Stock Comparison

PAVM vs UNH

PAVmed Inc vs UnitedHealth Group Inc

Who's the better investment? Let's break it down.

The Verdict

PAVM takes this one.

PAVM edges out the competition with a 1.5-point advantage. Not a blowout, but the numbers favor PAVM.

Winner

PAVM

PAVmed Inc

1.8

out of 10

Distressed

UNH

UnitedHealth Group Inc

0.3

out of 10

Distressed

Want to compare any two stocks?

Valuation

PAVM

Metric

UNH

$46M

Market Cap

$365.5B

114.1

P/E Ratio

Lower may indicate better value

30.3

N/A

Forward P/E

18.2

N/A

Price/Book

6.4

N/A

EV/EBITDA

16.8

Profitability & Growth

PAVM

Metric

UNH

564.8%

Profit Margin

2.7%

-205.6%

Gross Margin

18.5%

-30797.2%

Operating Margin

4.1%

1.0%

Return on Equity

12.4%

0.9%

Return on Assets

3.9%

-97.6%

Revenue Growth

9.7%

$-17.84

EPS

$13.24

Financial Health

PAVM

Metric

UNH

0.3

Debt-to-Equity

Lower = less leverage

0.8

0.2

Current Ratio

Above 1.0 is healthy

0.9

0.6

Beta

Lower = less volatile

0.6

None

Dividend Yield

2.3%

Risk Comparison

PAVM

Overall

Aggressive

Financial

High

Market

Medium

Competitive

Medium

Execution

High

Regulatory

Medium

What Could Go Wrong

PAVmed Inc. faces immediate and critical financial risk with only $6.5 million in cash against quarterly operating expenses of $8.1 million as of Q1 2026. Failure to secure substantial new funding for...

Red Flags

🚩PAVmed Inc. consolidated cash balance of $6.5 million as of Q1 2026 vs. $8.1 million in quarterly op...
🚩Persistent high cash burn rate at the parent company without meaningful offsetting revenue generatio...
🚩High likelihood of significant future shareholder dilution for PAVmed Inc. common stock, given ongoi...

UNH

Overall

Moderate

Financial

Low

Market

Medium

Competitive

Low

Execution

Low

Regulatory

High

What Could Go Wrong

The ongoing DOJ criminal and civil investigation, if it leads to significant penalties, forced divestitures, or operational restrictions, could severely impact Optum's growth trajectory and UNH's over...

Red Flags

🚩DOJ criminal and civil investigation: Presents an unquantified but potentially significant regulator...
🚩Reported membership contracting by 1.3 million in 2026 (from secondary source): If verified in futur...
🚩Very low insider ownership (0.28%): While common for mega-caps, it suggests less direct alignment wi...

Competitive Moat

PAVM

Rating

🛡️ None

Trend

📈 Expanding

Intangible Assets/IP

UNH

Rating

🛡️ Wide

Trend

➡️ Stable to Expanding

Efficient ScaleSwitching CostsIntangible Assets/IP (data, analytics, proprietary care models)Brand Power

Investment Thesis

PAVM1.8/10

If PAVmed Inc. successfully secures near-term financing for its parent operations (e.g., $30M+ by Q3 2026) and Lucid Diagnostics significantly accelerates EsoGuard commercialization (e.g., reaching $5M+ quarterly revenue by Q4 2026 with expanding reimbursement) alongside Veris Health achieving FDA 510(k) clearance in late 2026, then the combined entity could see its market capitalization re-rate s...

Full PAVM Analysis

UNH0.3/10

If Optum continues to expand its health services and technology footprint at high-single-digit to low-double-digit rates, while UnitedHealthcare maintains stable profitability and manages its medical loss ratio, then UNH will deliver consistent EPS growth (high-single digits) and dividend increases. This makes UNH a reliable compounder for long-term capital appreciation and income, not a high-grow...

Full UNH Analysis

Price Targets & Strategy

Price Targets & Entry/Exit Strategy

Growth Catalysts

Growth Catalysts Comparison

Market Sentiment

Market Sentiment Analysis

The Deep Dive

PAVM1.8/10

PAVmed Inc. remains an extremely speculative investment. While Lucid Diagnostics (a subsidiary) shows nascent commercial progress with $1.3M in Q1 2026 EsoGuard revenue and 3,177 tests processed, PAVmed Inc.'s consolidated financial health is critically weak. The Q1 2026 report reveals only $6.5 million in cash and equivalents against $8.1 million in quarterly operating expenses, implying a cash runway of less than one quarter. This immediate liquidity concern for the parent company, coupled wit...

Full PAVM Analysis

UNH0.3/10

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company capable of 10x growth within 3-5 years. Its immense scale, market maturity, and regulatory landscap...

Full UNH Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →View Top 100 →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.